Filter Results:
- Full text PDF available (50)
Publication Year
1978
2019
- This year (16)
- Last 5 years (55)
- Last 10 years (124)
Publication Type
Co-author
Journals and Conferences
Learn More
- Michael W. Fried, Mitchell L. Shiffman, +11 authors Jian Yu
- The New England journal of medicine
- 2002
BACKGROUND
Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C… (More)
- John McHutchison, Eric J. Lawitz, +17 authors Mark S Sulkowski
- The New England journal of medicine
- 2009
BACKGROUND
Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these… (More)
- Alexander Thompson, Andrew J. Muir, +32 authors John McHutchison
- Gastroenterology
- 2010
BACKGROUND & AIMS
We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated… (More)
- I M for the New Paradigm of HCV Therapy Meeting Part Jacobson, Stuart Gordon, +20 authors David R. Nelson
- The New England journal of medicine
- 2013
BACKGROUND
Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon… (More)
- Arun J Sanyal, C Campbell-Sargent, +6 authors John N. Clore
- Gastroenterology
- 2001
BACKGROUND AND AIMS
The pathogenesis of nonalcoholic steatohepatitis (NASH) is unknown. We tested the hypothesis that NASH is associated with 2 defects: (1) peripheral insulin resistance, which… (More)
- John McHutchison, Stuart Gordon, +7 authors Janice K. Albrecht
- The New England journal of medicine
- 1998
BACKGROUND
Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b… (More)
- Patrick Marcellin, Elizabeth Jenny Heathcote, +22 authors Franck Rousseau
- The New England journal of medicine
- 2008
BACKGROUND
Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase.
… (More)
- Kris V. Kowdley, Stuart Gordon, +22 authors Michael W. Fried
- The New England journal of medicine
- 2014
BACKGROUND
High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor… (More)
- Mitchell L. Shiffman, Fredy Suter, +8 authors Stefan Zeuzem
- The New England journal of medicine
- 2007
BACKGROUND
Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for… (More)
- P Ferenci, Michael W. Fried, +10 authors K Rajender Reddy
- Journal of hepatology
- 2005
BACKGROUND/AIMS
Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy.
METHODS
Retrospective analysis… (More)